Evidence map›Paper›PMID 42871461›Full record

ArticleFrontiers in pharmacology2026

MolecureAI: an agentic AI platform for autonomous drug discovery.

Mohamed Amine Chadi, Asmaa Amzil, Hajar Ezzahoud, Hajar Mousannif

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohamed Amine Chadi *Laboratory of Computer Science and Smart Systems (LISI), Faculty of Sciences Semlalia, Cadi Ayyad University, Marrakech, Morocco.
Asmaa Amzil *Laboratory of Computer Science and Smart Systems (LISI), Faculty of Sciences Semlalia, Cadi Ayyad University, Marrakech, Morocco.
Hajar Ezzahoud *Laboratory of Computer Science and Smart Systems (LISI), Faculty of Sciences Semlalia, Cadi Ayyad University, Marrakech, Morocco.
Hajar Mousannif *Laboratory of Computer Science and Smart Systems (LISI), Faculty of Sciences Semlalia, Cadi Ayyad University, Marrakech, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accelerating the identification of viable drug candidates across therapeutic areas demands autonomous systems for molecular generation that enforce chemical correctness by structural invariants rather than model capability. We present MolecureAI, an autonomous AI agent architecture for closed-loop drug discovery with cost-ordered cascade evaluation that addresses four capability gaps unresolved across the field: autonomous design strategy selection, persistent cross-campaign structural memory, in-loop ADMET safety gating, and literature-scale evidence integration into the generative loop. A cost-ordered cascade concentrates full structure-based evaluation on a small pre-filtered survivor set, achieving a

Indexed as

ADMET safety gatingautonomous drug discoverybenchmark target validationcampaign memorycost-ordered cascadeLLM agentmolecular generationtool orchestration

Identifiers

PMID42871461
PMCPMC13658513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.